Cargando…

Epigenetic therapies for neuroblastoma: immunogenicity awakens

The development of immunotherapies for neuroblastoma remains challenging owing to the low immunogenicity of neuroblastoma cells, as reflected by the low expression of one of the main triggers of immune recognition, the major histocompatibility complex class I (MHC‐I). Cornel et al. showed that epige...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiménez, Carlos, Moreno, Lucas, Segura, Miguel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10158771/
https://www.ncbi.nlm.nih.gov/pubmed/36840349
http://dx.doi.org/10.1002/1878-0261.13404

Ejemplares similares